ITT-PMS Ext
What it found
A paper reports the results; we have not read it yet. See Papers below.
What was tested
Treatment tested
- Rituximab
B-lymphocyte antigen CD20 binding agent
What it measured
Main measures
The time to progression ≥ 1,0 step on the EDSS scale
Disability progression
Other measures (1)
•Tests of walking ability and hand function
Walking and mobilityArm and hand function
Who could take part
Progressive MS
Inclusion: •Completed the ITT-MS trial (EudraCT number 2008-002626-11) Exclusion: •Eligible for any of the conventional MS therapies
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
To assess long-term stabilising effects of on neurological symptoms by regular IT administered monoclonal antibodies in MS.
Papers
Loading reviews and guidelines…
Linked trials
Extension of
PMSITPhase 2 · Completed
Links found where a registry record names another trial's registry number.
Related trials
- C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen R…
Phase 1 / Phase 2 · Not yet recruiting
Still running
- IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Prog…
Phase 1 · Paused
Still running
- Mintaka
Phase 2 · Recruiting
Still running
- The Effect of Rituximab on Cognitive and Hand Functions i…
Phase 2 · Recruiting
Still running
- ORATORIO-CP
Completed
No result found
- ORATORIO-Cort
Completed
No result found
History
Started
Oct 2012
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error